Safe and effective heat therapy for the management of MGD
Heat
The use of heat is a well-established and important adjunct therapy in the management of meibomian gland dysfunction. As an Eye Care Professional your challenge is to deliver this therapy to your patients effectively and safely.
TearRestore Warm Compress gives you this reassurance.
TearRestore Warm Compress
TearRestore’s open-eye warm compress delivers an effective, user friendly at-home treatment for MGD. Developed with assistance from industry leading physicians, TearRestore delivers therapeutic heat where it is needed while allowing the patient to see throughout treatment.
TearRestore is the first open-eye warm compress that allows patients to be active during their treatment. The mask has specifically designed, reusable, heat packs that target the oil glands of the eyelid while avoiding the globes, permitting the user to blink throughout treatment resulting in natural oil gland expression.
Benefits of
TearRestore Warm Compress
Targeted treatment
It targets the Meibomian glands, resulting in natural oil gland expression throughout use.
Consistent Heat
Supplies therapeutic heat (>40C) for a minimum of ten minutes every use, ensuring effective treatment
Convenient
The only open-eye warm compress that allows patients to be active during treatment
+51%
Symptom improvement
+90%
Tear breakup time
* Reference data below
+40%
Increase in Functional
Meibomian Glands
Find out more about TearRestore
Our Downloads
TearRestore Brochure
PDF, 440MB
Full TearRestore Clinical data
PDF, 929KB
Circle of Care - Heat
PDF, 250MB
Interested in using TearRestore Warm Compress in your practice?
Contact us to find out more about TearRestore and to order.
Read the news on
Positive Impact
The opticians’ favourite lens cleaning system is now more accessible than ever. We’ve removed the barrier of initial capital investment so you can focus on patient loyalty and practice growth.
Positive Impact (PI) will be showing its independent-only portfolio and launching two new diagnostic instruments.
This will be the debut for the return of the Keratron topographer range to the UK.
Throughout the month, more than 250 dry eye specialist practices across the UK joined forces with Positive Impact to help raise awareness of this growing eye health epidemic among the general public.
References
* Data was collected from a population of 22 eyes (age 18-89) of any race, gender or ethnicity, diagnosed with meibomian gland
dysfunction. Additional inclusion/exclusion criteria were applied. More information can be found at ClinicalTrials.gov